Nitobact / Nitobact SR
Nitrofurantoin 100 mg (Sustained Release)
Clinical Differentiators & Advantages
PCD Franchise Distribution
Verify if exclusive marketing and distribution rights for Nitobact / Nitobact SR are currently vacant in your target district.
Active Chemical Compounds & Molecular Architecture
Validated chemical entities, 2D skeletal bond diagrams, empirical molecular formulas, and receptor-level modes of action
Urinary antiseptic with zero cross-resistance, active against ESBL-producing E. coli and VRE strains.
Approved Clinical Indications & Disease Burden
Pharmacodynamic Mechanism of Action
Bacterial intracellular enzymes reduce Nitrofurantoin to reactive electrophilic intermediates that attack ribosomal RNA, DNA, and metabolic enzymes. High therapeutic concentrations are concentrated selectively in the urinary bladder with minimal systemic serum levels, preventing systemic microbiota disruption and avoiding cross-resistance.
Dosage & Administration Protocol
Treatment: 1 tablet twice daily for 7 days with food or milk. Prophylaxis: 1 tablet at bedtime.
Precautions, Warnings & Contraindications
B2B Commercial & Shipping Metrics
Moisture-sealed 5-ply export corrugation
Includes visual aids & promotional inputs
Private label & institutional supply
Standard pharmaceutical commercial tariff
Certificate of Analysis (COA), Stability Study Reports (Zone IVb), Finished Product Specs (FPS), and Material Safety Data Sheet (MSDS).
Frequently Prescribed & Stocked Together
Clinically aligned formulations commonly co-prescribed with Nitobact / Nitobact SR to improve patient outcomes and expand distributor portfolio basket size.
Ocon-OZ
Ofloxacin 200 mg + Ornidazole 500 mg
“The Powerful Weapon Against Severe Infections — Kill Infections Powerfully”